Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older
Completed · Phase 2 · Has a placebo group
Conditions studied: SARS-CoV-2
In brief
This clinical study will assess the safety, reactogenicity, and immunogenicity of 2 dose levels of mRNA-1273 Severe Acute Respiratory Syndrome coronavirus (SARS-COV-2) vaccine in adults 18 years of age or older.
Key facts
- Study ID
- NCT04405076
- Run by
- ModernaTX, Inc.
- People needed
- 660
- Starts
- 2020-05-29
- Expected to finish
- 2021-10-28
- Last updated by the study team
- 2022-12-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- Meridian Clinical Research — Savannah, Georgia, United States
- Alliance for Multispecialty Research — Newton, Kansas, United States
- Alliance for Multispecialty Research — Kansas City, Missouri, United States
- Meridian Clinical Research — Norfolk, Nebraska, United States
- Trial Management Associates — Wilmington, North Carolina, United States
- Meridian Clinical Research — Dakota Dunes, South Dakota, United States
- Benchmark Research — Austin, Texas, United States
- Benchmark Research — San Angelo, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.